Outpatient Treatment of Severe and Enduring Anorexia Nervosa

NCT ID: NCT05708404

Last Updated: 2023-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-01

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Approximately 20-30 % of individuals with the eating disorder anorexia nervosa develop an enduring form of the illness. In this study a new treatment for patients with severe and enduring anorexia nervosa was described. The treatment is flexible and aims at enhancing quality of life. The participants consisted of all referrals resulting in an assessment or treatment period at the unit between May 2017 and May 2022. The study was a registry study. Information regarding patient characteristics, treatment goals, and the course of treatment was gathered from medical records.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anorexia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Outpatient treatment of severe and enduring anorexia nervosa

A novel outpatient treatment of severe and enduring anorexia nervosa, aiming at enhancing quality of life and minimizing harm

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* A referral resulting in an assessment or treatment period at the unit for patients with severe and enduring anorexia nervosa at the HUS Helsinki University Hospital between May 2017 and May 2022.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Helsinki University Central Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Monica Algars

Ph.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jaana Suokas, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

HUS Helsinki Central Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HUS Syömishäiriöyksikkö

Helsinki, PL 282, Finland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland

References

Explore related publications, articles, or registry entries linked to this study.

Algars M, Oshukova S, Suokas J. A novel outpatient treatment model for patients with severe and enduring anorexia nervosa: an observational study of patient characteristics, treatment goals, and treatment course. J Eat Disord. 2023 Sep 6;11(1):150. doi: 10.1186/s40337-023-00877-x.

Reference Type DERIVED
PMID: 37674214 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PISARAAVO

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.